1. Home
  2. RLMD vs UBXG Comparison

RLMD vs UBXG Comparison

Compare RLMD & UBXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RLMD
  • UBXG
  • Stock Information
  • Founded
  • RLMD 2004
  • UBXG 2018
  • Country
  • RLMD United States
  • UBXG China
  • Employees
  • RLMD N/A
  • UBXG N/A
  • Industry
  • RLMD Biotechnology: Pharmaceutical Preparations
  • UBXG
  • Sector
  • RLMD Health Care
  • UBXG
  • Exchange
  • RLMD Nasdaq
  • UBXG Nasdaq
  • Market Cap
  • RLMD 11.5M
  • UBXG 9.5M
  • IPO Year
  • RLMD N/A
  • UBXG 2024
  • Fundamental
  • Price
  • RLMD $0.30
  • UBXG $3.50
  • Analyst Decision
  • RLMD Hold
  • UBXG
  • Analyst Count
  • RLMD 4
  • UBXG 0
  • Target Price
  • RLMD $4.25
  • UBXG N/A
  • AVG Volume (30 Days)
  • RLMD 2.1M
  • UBXG 36.4K
  • Earning Date
  • RLMD 03-18-2025
  • UBXG 12-31-2024
  • Dividend Yield
  • RLMD N/A
  • UBXG N/A
  • EPS Growth
  • RLMD N/A
  • UBXG N/A
  • EPS
  • RLMD N/A
  • UBXG N/A
  • Revenue
  • RLMD N/A
  • UBXG $51,600,106.00
  • Revenue This Year
  • RLMD N/A
  • UBXG N/A
  • Revenue Next Year
  • RLMD N/A
  • UBXG N/A
  • P/E Ratio
  • RLMD N/A
  • UBXG N/A
  • Revenue Growth
  • RLMD N/A
  • UBXG N/A
  • 52 Week Low
  • RLMD $0.28
  • UBXG $0.26
  • 52 Week High
  • RLMD $7.22
  • UBXG $35.44
  • Technical
  • Relative Strength Index (RSI)
  • RLMD 30.81
  • UBXG N/A
  • Support Level
  • RLMD $0.28
  • UBXG N/A
  • Resistance Level
  • RLMD $0.36
  • UBXG N/A
  • Average True Range (ATR)
  • RLMD 0.04
  • UBXG 0.00
  • MACD
  • RLMD 0.02
  • UBXG 0.00
  • Stochastic Oscillator
  • RLMD 7.21
  • UBXG 0.00

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

About UBXG U-BX Technology Ltd. Ordinary Shares

U-BX Technology Ltd is focused on providing value-added services using artificial intelligence-driven technology to businesses within the insurance industry, including insurance carriers and brokers. It helps institutional clients obtain visibility on various social media platforms and generate revenue based on consumers' clicks, views, or its clients' promotion time through those channels. The company derives a majority of its revenue by providing digital promotion services to its clients and also engages in providing risk assessment services, and value-added bundled benefits. It has developed an algorithm named Magic Mirror, to calculate payout risks for insurance carriers to underwrite auto insurance coverage. Geographically, all of the company's revenue is derived from Mainland China.

Share on Social Networks: